MY192464A - Sustained-release preparation of cilostazol - Google Patents

Sustained-release preparation of cilostazol

Info

Publication number
MY192464A
MY192464A MYPI2019004733A MYPI2019004733A MY192464A MY 192464 A MY192464 A MY 192464A MY PI2019004733 A MYPI2019004733 A MY PI2019004733A MY PI2019004733 A MYPI2019004733 A MY PI2019004733A MY 192464 A MY192464 A MY 192464A
Authority
MY
Malaysia
Prior art keywords
cilostazol
sustained
release preparation
release
pharmaceutically acceptable
Prior art date
Application number
MYPI2019004733A
Inventor
Bo Kyung Kim
Kwang-Ho Cho
Youn Woong Choi
Sang Min Cho
Original Assignee
Korea United Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea United Pharm Inc filed Critical Korea United Pharm Inc
Publication of MY192464A publication Critical patent/MY192464A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided is a sustained-release preparation of cilostazol including cilostazol or a pharmaceutically acceptable salt thereof, and a neutral water-insoluble methacrylic acid copolymer as a matrix base for sustained release. (FIG.1)
MYPI2019004733A 2018-08-17 2019-04-09 Sustained-release preparation of cilostazol MY192464A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180096354A KR102138253B1 (en) 2018-08-17 2018-08-17 Sustained release preparation of cilostazol
PCT/KR2019/004224 WO2020036284A1 (en) 2018-08-17 2019-04-09 Sustained-release formulation of cilostazol

Publications (1)

Publication Number Publication Date
MY192464A true MY192464A (en) 2022-08-22

Family

ID=69524815

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019004733A MY192464A (en) 2018-08-17 2019-04-09 Sustained-release preparation of cilostazol

Country Status (3)

Country Link
KR (1) KR102138253B1 (en)
MY (1) MY192464A (en)
WO (1) WO2020036284A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070024254A (en) * 2005-08-26 2007-03-02 한국오츠카제약 주식회사 Sustained-release tablets comprising cilostazol
US20110165236A1 (en) 2006-09-22 2011-07-07 Biokey, Inc. Controlled release hydrogel formulation
JP4879351B2 (en) * 2007-10-19 2012-02-22 大塚製薬株式会社 Pharmaceutical solid formulation
EP2408437A1 (en) * 2009-03-18 2012-01-25 Evonik Röhm GmbH Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
KR101068475B1 (en) * 2009-12-29 2011-09-28 환인제약 주식회사 A sustained composition comprising cilostazol and the method thereof
KR101282847B1 (en) * 2011-07-27 2013-07-05 조선대학교산학협력단 Solid dispersion containing cilostazol and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
KR20200020542A (en) 2020-02-26
WO2020036284A1 (en) 2020-02-20
KR102138253B1 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
PH12019502325A1 (en) Sustained release delivery systems comprising traceless linkers
AU2018271990A1 (en) Covalent inhibitors of KRAS
MX2016014320A (en) Extended release suspension compositions.
WO2017037594A3 (en) Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition
PH12020551263A1 (en) Sustained release formulations of bempedoic acid
MY187358A (en) Modified release orally administered amino acid formulations
SG11201909590XA (en) Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
WO2019108021A3 (en) Pharmaceutical composition comprising tofacitinib
PH12019500849A1 (en) Naphthyridinone derivatives and their use inthe treatment of arrhythmia
MX2018012224A (en) Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof.
PH12019500919A1 (en) Esomeprazole~containing complex capsule and preparation method therefor
MX2021003606A (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases.
MX2019002901A (en) Treatment of multiple sclerosis with chs-131.
MY192464A (en) Sustained-release preparation of cilostazol
MX2019001032A (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof.
JOP20170197A1 (en) The novel formulation comprising a benzimidazole derivative
MX2019001771A (en) Solid pharmaceutical composition comprising amorphous sofosbuvir.
PH12020500228A1 (en) Pharmacutical composition comprising remogliflozin and antidiabetic agent
EA202190561A1 (en) AG10 PREPARATIONS
MX2019004375A (en) Bromodomain inhibitors.
WO2019151964A3 (en) Orally disintegrating formulations of saxagliptin
WO2021080931A8 (en) Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising the same and their use
MX2021011795A (en) Pharmaceutical composition comprising esomeprazole or pharmaceutically acceptable salt thereof and having double-release profile.
EA202191603A1 (en) PHARMACEUTICAL COMPOSITION
MX354579B (en) Vaginal ring including meloxicam and an agent for modulating the release of the active principle, which can be used as a continuous-use contraceptive in women.